J&J Procrit Grows In Q1 Despite Challenges For ESAs
This article was originally published in The Pink Sheet Daily
U.S. sales of the erythropoiesis-stimulating agent grew 1 percent in Q1 on strong sales in the hospital and retail market.
You may also be interested in...
After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Court denies injunction sought by J&J to stop Amgen discounts based on amount of anemia products purchased.